Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

42.88 +0.06 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Harrow Announces Third Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Earnings Scheduled For November 13, 2024
 
Via Benzinga
Earnings Outlook For Harrow
 
Via Benzinga
The Analyst Landscape: 4 Takes On Harrow
 
Via Benzinga
Navigating 5 Analyst Ratings For Harrow
 
Via Benzinga
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
From Harrow, Inc.
Via Business Wire
Harrow Announces Market Access Wins for VEVYE®
From Harrow, Inc.
Via Business Wire
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
From Harrow, Inc.
Via Business Wire
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Harrow, Inc.
Via Business Wire
Harrow Relaunches TRIESENCE®
From Harrow, Inc.
Via Business Wire
Harrow Announces Nashville Expansion
From Harrow, Inc.
Via Business Wire
Harrow to Present at Three Investor Conferences in September in New York
From Harrow, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers on Thursday morning with all of the latest news this morning! 
Via InvestorPlace
HROW Stock Earnings: Harrow Beats EPS, Misses Revenue for Q2 2024
HROW stock results show that Harrow beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Harrow Announces Second Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
From Harrow, Inc.
Via Business Wire
Harrow to Attend 2024 ASRS Annual Meeting
From Harrow, Inc.
Via Business Wire
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
From Harrow, Inc.
Via Business Wire
Top 3 Health Care Stocks That May Crash This Quarter
 
Via Benzinga
HROW Stock Earnings: Harrow Beats EPS, Beats Revenue for Q2 2023
HROW stock results show that Harrow beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2023. 
Via InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Harrow Provides TRIESENCE® Relaunch Update
From Harrow, Inc.
Via Business Wire
The Top 7 Growth Stocks to Buy and Hold Until 2030
These seven growth stocks look poised to outperform through 2030 and beyond with market-beating upside potential. 
Via InvestorPlace
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
From Harrow, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.